Enterome SA has started a Phase 1 study of its lead small molecule drug directed at the gut microbiome. The candidate drug targets the FimH protein as a means of blocking inflammation in Crohn’s disease. ---Subscribe to MedNous to access this article--- Clinical Research Company News
